Core Scientific, Inc. (CORZ) Chief Legal and Administrative Officer Todd M. Duchene sold 10,000 shares on September 21, 2026, at a weighted average price of $18.3746 per share. The shares were sold in multiple transactions at prices ranging from $17.81 to $18.64, inclusive.
The sale was made under a Rule 10b5-1 trading plan adopted December 5, 2025. Duchene reported 1,197,896 shares held directly following the sale. A separate holding entry lists 700,000 shares held by a grantor retained annuity trust of which he is the sole trustee.
Core Scientific, Inc. (CORZ) director Eric Stanton Weiss purchased 6,000 shares of Common Stock on September 15, 2026, in a purchase classified as an open market or private transaction at $16.33 per share. Following this trade, he directly holds 265,262 shares of Core Scientific common stock. No Rule 10b5-1 trading plan is reported for this transaction.
Core Scientific, Inc. (CORZ) reports that its Chief Legal and Administrative Officer, Todd M. Duchene, sold 10,000 shares of common stock on September 14, 2026 in an open-market transaction at a weighted average price of $17.14 per share, under a Rule 10b5-1 trading plan adopted on December 5, 2025.
After this sale, he continues to hold 1,207,896 shares of common stock directly and an additional 700,000 shares indirectly through a grantor retained annuity trust for which he is the sole trustee.
Core Scientific, Inc. (CORZ) reported that its Chief Legal and Administrative Officer, Todd M. Duchene, sold 10,000 shares of common stock on September 8, 2026 at a weighted average price of $18.6735 per share under a Rule 10b5-1 trading plan adopted on December 5, 2025, leaving him with 1,217,896 shares held directly. On September 9, 2026, he made a charitable donation of 95,000 Tranche 1 Warrants, each exercisable for one share of common stock at $6.81 per share until January 23, 2027, with 422,133 such warrants remaining. A separate transfer on September 10, 2026 moved 700,000 shares of common stock into a grantor retained annuity trust of which he is the sole trustee, which are now reported as held indirectly.
Core Scientific, Inc. (CORZ) reports updated electrical power status for its existing and planned data centers in Texas under ERCOT’s large-load review framework. At Denton, 297 Megawatts of existing power has been conditionally approved as “Base Load, Pathway (a)” and is classified as longstanding existing load not subject to the Batch Zero allocation process. An additional 74 Megawatts at Denton was previously incorporated in ERCOT’s 2025 Regional Transmission Plan study cases and is also outside the Batch Zero process.
At Pecos, 300 Megawatts of existing power and an additional 300 Megawatts of “Studied Load” have been conditionally approved in Batch Zero as “Base Load, Pathway (b).” All required documentation and financial collateral for Pecos have been submitted and posted, though final allocation and load ramp will follow completion of Batch Zero. At Hunt, 431 Megawatts of planned power has been conditionally approved in Batch Zero as “Base Load, Advancing Large Load, Pathway (e),” with interconnection studies completed, ERCOT stability approval received, financial collateral posted, long-lead equipment ordered, and construction commenced.
Core Scientific, Inc. (CORZ) officer Todd M. Duchene, Chief Legal and Administrative Officer, reported selling 10,000 shares of common stock on August 31, 2026 at a weighted average price of $16.23 per share under a Rule 10b5-1 trading plan. After this sale, he held 1,927,896 shares directly.
Core Scientific, Inc. (CORZ) entered into committed senior secured credit facilities totaling $600 million, comprised of a $100 million senior secured revolving credit facility and a $500 million letter of credit facility with a syndicate of banks led by JPMorgan Chase Bank, N.A. The facilities mature on the third anniversary of August 25, 2026, or, at the company’s election, the fourth anniversary, and are secured by a first‑priority lien on substantially all assets of Core Scientific and certain wholly owned domestic subsidiaries, which also guarantee the obligations.
Borrowings under the revolver bear interest at Adjusted Term SOFR + 1.750% (0.00% floor) or an alternate base rate + 0.75%. Letters of credit incur a 1.750% annual fee plus a 0.125% quarterly fronting fee, and a 0.250% annual commitment fee applies to unused portions of the facilities. As of closing, no amounts were outstanding, and the company disclosed a quarterly liquidity covenant of at least $150 million and a minimum market capitalization of $3,000 million as a condition to each borrowing under the revolver. A related press release states the facilities are expected to release approximately $300 million of restricted cash, improving capital efficiency as Core Scientific continues shifting its digital infrastructure business toward high‑density colocation services for AI‑related workloads.
Core Scientific, Inc. (CORZ) reported that its Chief Legal and Administrative Officer, Todd M. Duchene, sold 10,000 shares of common stock on August 24, 2026 in an open-market transaction at a weighted average price of $17.4493 per share. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 5, 2025. After this transaction, Duchene directly holds 1,937,896 shares of Core Scientific common stock.
The filing notes that the 10,000 shares were sold in multiple trades at prices ranging from $17.17 to $17.77 per share.
Core Scientific, Inc. (CORZ) director Elizabeth Crain purchased Core Scientific common stock in the open market. She bought 6,000 shares of common stock on 2026-08-20 at a weighted average price of $18.3324 per share, in multiple trades between $18.27 and $18.345. Following this transaction, she directly holds 71,348 shares of Core Scientific common stock.
Core Scientific, Inc./tx (CORZ) director Eric Stanton Weiss reported an open-market purchase of 7,000 shares of Common Stock on August 18, 2026, at a weighted average price of $19.194 per share. After this transaction, he directly holds 259,262 CORZ shares. The price reflects multiple trades between $18.785 and $19.595 per share.